View Older Stories View More Recent Stories

Sep 14, 2016 04:01PM Biogen to Report Third Quarter 2016 Financial Results on October 26, 2016
Sep 14, 2016 07:30AM New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting
Sep 8, 2016 07:34AM Biogen (BIIB) to Present Findings from MS Cost of Illness Study at ECTRIMS; Will Include Tecfidera Data
Sep 8, 2016 07:30AM Biogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio
Sep 1, 2016 04:05PM Biogen's (BIIB) Aducanumab Receives FDA Fast-Track Designation as Alzheimer’s Disease Treatment
Sep 1, 2016 04:01PM Biogen to Present at the Morgan Stanley Global Healthcare Conference
Sep 1, 2016 04:01PM Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation
Aug 31, 2016 01:15PM Biogen (BIIB) Announces Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Aducanumab to Treat AD
Aug 31, 2016 01:13PM Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab
Aug 9, 2016 09:00AM Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company
Aug 1, 2016 07:34AM Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA
Aug 1, 2016 07:30AM Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
Jul 21, 2016 07:00AM Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion
Jul 18, 2016 07:32AM Biogen (BIIB), Sobi to Present Updated ELOCTATE Data at Hemophilia 2016 World Congress
Jul 18, 2016 07:30AM Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data from Extended Half-Life Hemophilia Therapies at World Federation of Hemophilia 2016 World Congress
Jul 17, 2016 09:05PM SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency
Jul 5, 2016 08:04AM Biogen (BIIB), AbbVie (ABBV) Receive Marketing Approval in Europe for ZINBRYTA as MS Treatment
Jul 5, 2016 08:00AM Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
Jun 28, 2016 06:36AM Cognizant's (CTSH) SmartTrials Platform Selected for Use by Biogen (BIIB)
Jun 28, 2016 06:00AM Biogen Selects Cognizant's SmartTrials Platform
Jun 21, 2016 11:00AM Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology
Jun 20, 2016 04:01PM Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016
Jun 9, 2016 07:09AM Biogen (BIIB), Samsung Present Efficacy, Safety Data on BENEPALI, and FLIXABI at EULAR 2016
Jun 9, 2016 07:08AM New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio
Jun 7, 2016 07:33AM Biogen (BIIB) Phase 2 Study of Opicinumab Missed Primary Endpoint
Jun 7, 2016 07:30AM Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
Jun 1, 2016 12:09PM Biogen's (BIIB) Aducanumab Accepted into EMA PRIME Program
Jun 1, 2016 11:45AM Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program
May 31, 2016 08:48AM Biogen (BIIB), Samsung's FLIXABI Granted Marketing Approval in Europe
May 31, 2016 07:31AM Biogen (BIIB) Announces Receipt of Positive CHMP Opinion for TYSABRI in RRMS Patients
May 31, 2016 07:30AM Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy
May 31, 2016 07:23AM Biogen (BIIB), AbbVie (ABBV) Granted FDA Approval of ZINBRYTA for MS
May 30, 2016 02:05AM FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union
May 27, 2016 10:27PM Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
May 27, 2016 09:38PM Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple Sclerosis
May 27, 2016 09:36PM Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
May 19, 2016 04:01PM Biogen Announces Webcast of Virtual Annual Meeting of Stockholders
May 16, 2016 07:14AM Biogen (BIIB), Univ. of Pennsylvania Enter Development Collaboration Covering Multiple Gene Therapy Technologies
May 16, 2016 07:00AM Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs
May 13, 2016 06:47AM Biogen (BIIB), Sobi Announce EC Approval of Alprolix as Haemophilia B Treatment
May 13, 2016 02:47AM Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B
May 3, 2016 07:31AM Biogen (BIIB) Plans to Spinoff Hemophilia Business into Independent, Publicly-Traded Company
May 3, 2016 07:30AM Biogen Announces Intent to Spin off Its Hemophilia Business
Apr 29, 2016 07:39AM Biogen (BIIB), AbbVie (ABBV) Receive Positive CHMP Opinion on ZINBRYTA in MS
Apr 29, 2016 07:39AM Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
Apr 27, 2016 09:15AM Biogen (BIIB) Names New R&D Executive
Apr 27, 2016 09:15AM Biogen Appoints Michael Ehlers Executive Vice President, Research and Development
Apr 21, 2016 07:15AM Biogen Reports First Quarter 2016 Revenues of $2.7 Billion
Apr 20, 2016 08:13AM Biogen (BIIB), AbbVie (ABBV) Present Data at AAN Highlighting Impact of ZINBRYTA on Cognitive Outcomes and Targeted MOA
Apr 20, 2016 07:30AM Data Presented at AAN Highlight Impact of ZINBRYTA™ (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action
View More Recent Stories View Older Stories